216 related articles for article (PubMed ID: 37626832)
1. Human Blood Serum Can Diminish EGFR-Targeted Inhibition of Squamous Carcinoma Cell Growth through Reactivation of MAPK and EGFR Pathways.
Kamashev D; Shaban N; Lebedev T; Prassolov V; Suntsova M; Raevskiy M; Gaifullin N; Sekacheva M; Garazha A; Poddubskaya E; Sorokin M; Buzdin A
Cells; 2023 Aug; 12(16):. PubMed ID: 37626832
[TBL] [Abstract][Full Text] [Related]
2. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
Ather F; Hamidi H; Fejzo MS; Letrent S; Finn RS; Kabbinavar F; Head C; Wong SG
PLoS One; 2013; 8(2):e56112. PubMed ID: 23405260
[TBL] [Abstract][Full Text] [Related]
3. Human blood serum can donor-specifically antagonize effects of EGFR-targeted drugs on squamous carcinoma cell growth.
Kamashev D; Sorokin M; Kochergina I; Drobyshev A; Vladimirova U; Zolotovskaia M; Vorotnikov I; Shaban N; Raevskiy M; Kuzmin D; Buzdin A
Heliyon; 2021 Mar; 7(3):e06394. PubMed ID: 33748471
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib and gefitinib responsiveness in head and neck cancer cell lines--a comparing analysis with cetuximab.
Hartmann S; Neckel N; Seher A; Mutzbauer G; Brands RC; Linz C; Kübler AC; Müller-Richter UD
Clin Oral Investig; 2016 May; 20(4):759-69. PubMed ID: 26297130
[TBL] [Abstract][Full Text] [Related]
5. The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines.
Boeckx C; Van den Bossche J; De Pauw I; Peeters M; Lardon F; Baay M; Wouters A
BMC Res Notes; 2015 Jun; 8():203. PubMed ID: 26032726
[TBL] [Abstract][Full Text] [Related]
6. Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations.
Wheler JJ; Tsimberidou AM; Falchook GS; Zinner RG; Hong DS; Fok JY; Fu S; Piha-Paul SA; Naing A; Kurzrock R
Mol Cancer Ther; 2013 Oct; 12(10):2167-75. PubMed ID: 23963360
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.
Ansell A; Jedlinski A; Johansson AC; Roberg K
J Oral Pathol Med; 2016 Jan; 45(1):9-16. PubMed ID: 25677871
[TBL] [Abstract][Full Text] [Related]
8. Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells.
Yoshioka M; Ohashi S; Ida T; Nakai Y; Kikuchi O; Amanuma Y; Matsubara J; Yamada A; Miyamoto S; Natsuizaka M; Nakagawa H; Chiba T; Seno H; Muto M
J Exp Clin Cancer Res; 2017 Aug; 36(1):101. PubMed ID: 28764725
[TBL] [Abstract][Full Text] [Related]
9. EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells.
Bryant JA; Finn RS; Slamon DJ; Cloughesy TF; Charles AC
Cancer Biol Ther; 2004 Dec; 3(12):1243-9. PubMed ID: 15611621
[TBL] [Abstract][Full Text] [Related]
10. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
11. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.
Huang S; Li C; Armstrong EA; Peet CR; Saker J; Amler LC; Sliwkowski MX; Harari PM
Cancer Res; 2013 Jan; 73(2):824-33. PubMed ID: 23172311
[TBL] [Abstract][Full Text] [Related]
12. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.
Brand TM; Dunn EF; Iida M; Myers RA; Kostopoulos KT; Li C; Peet CR; Wheeler DL
Cancer Biol Ther; 2011 Sep; 12(5):436-46. PubMed ID: 21725209
[TBL] [Abstract][Full Text] [Related]
13. Is EGFR really a therapeutic target in head and neck cancers?
Agarwal V; Subash A; Nayar RC; Rao V
J Surg Oncol; 2019 May; 119(6):685-686. PubMed ID: 30701564
[TBL] [Abstract][Full Text] [Related]
14. Anti-EGFR antibody cetuximab is secreted by oral squamous cell carcinoma and alters EGF-driven mesenchymal transition.
Fujiwara T; Eguchi T; Sogawa C; Ono K; Murakami J; Ibaragi S; Asaumi JI; Okamoto K; Calderwood SK; Kozaki KI
Biochem Biophys Res Commun; 2018 Sep; 503(3):1267-1272. PubMed ID: 30017201
[TBL] [Abstract][Full Text] [Related]
15. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
[TBL] [Abstract][Full Text] [Related]
16. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
17. MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.
Koch AT; Love-Homan L; Espinosa-Cotton M; Stanam A; Simons AL
Cancer Res; 2015 Apr; 75(8):1657-67. PubMed ID: 25712126
[TBL] [Abstract][Full Text] [Related]
18. Human Blood Serum Counteracts EGFR/HER2-Targeted Drug Lapatinib Impact on Squamous Carcinoma SK-BR-3 Cell Growth and Gene Expression.
Shaban N; Raevskiy M; Zakharova G; Shipunova V; Deyev S; Suntsova M; Sorokin M; Buzdin A; Kamashev D
Biochemistry (Mosc); 2024 Mar; 89(3):487-506. PubMed ID: 38648768
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.
Yu W; Lu W; Chen G; Cheng F; Su H; Chen Y; Liu M; Pang X
Br J Pharmacol; 2017 Oct; 174(20):3608-3622. PubMed ID: 28749535
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
Song JY; Lee SW; Hong JP; Chang SE; Choe H; Choi J
Cancer Lett; 2009 Oct; 283(2):135-42. PubMed ID: 19380191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
